Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention European Union, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Micheál Martin, all published on August 16, 2026.
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention European Union, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Micheál Martin, all published on August 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Micheál Martin. Shared-story counts are live from our verified record — not editorial picks.
For biopharma, Ireland's HSE Drugs Group non-recommendation for Skyclarys highlights the mounting gap between EMA approval and national reimbursement in rare diseases. The decision, citing evidence limitations and price, leaves around 200 Irish patients without public access despite EU-wide authorization since February 2024.
Source: zimbabwestar.com · floridastatesman.com
Micheál Martin is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
